Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Progression-Free Survival in Ovarian Cancer Is Reflected in Epigenetic DNA Methylation Profiles

1 Jan 2011

Abstract excerpt

OBJECTIVE: Many patients with ovarian cancer disease relapse within 6 months after adjuvant chemotherapy, with a limited prognosis. Epigenetic modifications have been shown to play an important role in tumor development and formation. Therefore, global analysis of DNA methylation patterns might reveal specific CpG sites that correlate with progression-free interval (PFI) after therapy. METHODS: Twenty samples of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epigenetics and DNA Methylation
Share to Ferroptosis and cancer prognosis
Share to Telomeres, Telomerase, and Senescence

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 21577013
DOI: 10.1159/000327746

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Progression-Free Survival in Ovarian Cancer Is Reflected in Epigenetic DNA Methylation ProfilesPMID 21577013Read ↗

DNA methylation changes in ovarian cancer: Implications for early diagnosis, prognosis and treatmentSemantic proximity Read ↗

Global methylation profiling in serous ovarian cancer is indicative for distinct aberrant DNA methylation signatures associated with tumor aggressiveness and disease progressionSemantic proximity Read ↗

RUNX3 and CAMK2N1 hypermethylation as prognostic marker for epithelial ovarian cancerSemantic proximity Read ↗

Promoter CpG Island Methylation of Genes in Key Cancer Pathways Associates with Clinical Outcome in High-Grade Serous Ovarian CancerSemantic proximity Read ↗

Development and validation of a DNA methylation signature to predict the progression-free survival in patients with advanced-stage ovarian cancerSemantic proximity Read ↗

Genome-wide DNA methylome analysis identifies methylation signatures associated with survival and drug resistance of ovarian cancersSemantic proximity Read ↗

Prognostic value of BRCA1 promoter methylation for patients with epithelial ovarian cancer.Semantic proximity Read ↗

Abnormal methylation characteristics predict chemoresistance and poor prognosis in advanced high-grade serous ovarian cancerSemantic proximity Read ↗

DNA methylation landscapes of matched primary and recurrent high grade serous ovarian cancers are preserved throughout disease progression and chemoresistanceSemantic proximity Read ↗

Association of somatic DNA methylation variability with progression-free survival and toxicity in ovarian cancer patientsSemantic proximity Read ↗

Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathwaysSemantic proximity Read ↗

Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.